General MedicationsORALGeneric

ERLOTINIB HYDROCHLORIDE

Standard Dose

EQ 25MG BASE

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Discontinued

Summary

Approval overview ERLOTINIB HYDROCHLORIDE is listed in Drugs@FDA under application 216342 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient ERLOTINIB HYDROCHLORIDE Form and strength TABLET;ORAL - EQ 25MG BASE Sponsor EUGIA PHARMA Submission history Latest submission status date: 2022-06-22 00:00:00.

Structured Monograph

Clinical summary

Approval overview ERLOTINIB HYDROCHLORIDE is listed in Drugs@FDA under application 216342 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ERLOTINIB HYDROCHLORIDE Form and strength TABLET;ORAL - EQ 25MG BASE Sponsor EUGIA PHARMA Submission history Latest submission status date: 2022-06-22 00:00:00. Submission type: ORIG.

Monitoring

• Marketing status: Discontinued
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.